StockMacro
Menu

Assembly Biosciences

$22.19 -23% in 6 monthsMarket cap $454.4M

ASMB on XNAS, Health Care, Assembly Biosciences, Inc, job postings

Measures activity, not value. Not investment advice.

Quarterly revenue fell 73% to $3M, while short interest reached 15% of shares, 1.9 times a year earlier.

  • BadShares fell 40% over 12 months, with a net loss of $11.1M
  • WatchRevenue rose 80% over 12 months to $67M, but the latest quarter fell

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Industry
Pharmaceutical preparations (Health Care)
Employees
73
Website
assemblybio.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 18 Mar 2027 (an estimate: a year ago it reported on 19 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.0M, net loss $20.3M.
Quarter to 31 Dec 2021: revenue $0, net income -$60.3MQuarter to 31 Dec 2021: revenue $0, net income -$60.3MQuarter to 31 Mar 2022: revenue –, net income -$23.1MQuarter to 30 Jun 2022: revenue –, net income -$24.5MQuarter to 30 Sep 2022: revenue –, net income -$23.1MQuarter to 31 Dec 2022: revenue –, net income -$22.4MQuarter to 31 Mar 2023: revenue $0, net income -$18.9MQuarter to 31 Mar 2023: revenue $0, net income -$18.9MQuarter to 30 Jun 2023: revenue $0, net income -$16.9MQuarter to 30 Jun 2023: revenue $0, net income -$16.9MQuarter to 30 Sep 2023: revenue $0, net income -$14.4MQuarter to 30 Sep 2023: revenue $0, net income -$14.4MQuarter to 31 Dec 2023: revenue $7.2M, net income -$11.0MQuarter to 31 Dec 2023: revenue $7.2M, net income -$11.0MQuarter to 31 Mar 2024: revenue $5.8M, net income -$9.1MQuarter to 31 Mar 2024: revenue $5.8M, net income -$9.1MQuarter to 30 Jun 2024: revenue $8.5M, net income -$11.2MQuarter to 30 Jun 2024: revenue $8.5M, net income -$11.2MQuarter to 30 Sep 2024: revenue $6.8M, net income -$9.6MQuarter to 30 Sep 2024: revenue $6.8M, net income -$9.6MQuarter to 31 Dec 2024: revenue $7.4M, net income -$10.3MQuarter to 31 Dec 2024: revenue $7.4M, net income -$10.3MQuarter to 31 Mar 2025: revenue $9.4M, net income -$8.8MQuarter to 31 Mar 2025: revenue $9.4M, net income -$8.8MQuarter to 30 Jun 2025: revenue $9.6M, net income -$10.2MQuarter to 30 Jun 2025: revenue $9.6M, net income -$10.2MQuarter to 30 Sep 2025: revenue $10.8M, net income -$9.2MQuarter to 30 Sep 2025: revenue $10.8M, net income -$9.2MQuarter to 31 Dec 2025: revenue –, net income $22.1MQuarter to 31 Mar 2026: revenue $8.2M, net income -$9.1MQuarter to 31 Mar 2026: revenue $8.2M, net income -$9.1MQuarter to 30 Jun 2026: revenue $13.4M, net income -$3.9MQuarter to 30 Jun 2026: revenue $13.4M, net income -$3.9MQuarter to 30 Sep 2026: revenue $3.0M, net income -$20.3MQuarter to 30 Sep 2026: revenue $3.0M, net income -$20.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $60.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$3.0M-$20.3M
30 Jun 2026$13.4M-$3.9M
31 Mar 2026$8.2M-$9.1M
31 Dec 2025–$22.1M
30 Sep 2025$10.8M-$9.2M
30 Jun 2025$9.6M-$10.2M
31 Mar 2025$9.4M-$8.8M
31 Dec 2024$7.4M-$10.3M
30 Sep 2024$6.8M-$9.6M
30 Jun 2024$8.5M-$11.2M
31 Mar 2024$5.8M-$9.1M
31 Dec 2023$7.2M-$11.0M
30 Sep 2023$0-$14.4M
30 Jun 2023$0-$16.9M
31 Mar 2023$0-$18.9M
31 Dec 2022–-$22.4M
30 Sep 2022–-$23.1M
30 Jun 2022–-$24.5M
31 Mar 2022–-$23.1M
31 Dec 2021$0-$60.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $67.0M $37.2M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +80% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$11.1M -$38.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -31.8% -117% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -16.6% -104% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -4.6% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $314.3M $232.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$314.3M (net cash) -$232.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $14.59
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 6.8 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.1 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.5 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Assembly BiosciencesASMB (this company) $454.4Mloss6.8+80%-16.6%
Shattuck LabsSTTK $454.2Mloss–––
NeurogeneNGNE $458.5Mloss–––
Gyre TherapeuticsGYRE $460.8Mloss4.0+8.4%-30.1%
BlossomHill TherapeuticsBLSM $461.2M––––
DiaMedica TherapeuticsDMAC $445.1Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$238K

bought $0, sold $238K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+12%

102 13F filers vs 91

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

94%

19.2M shares held by 13F filers (30 Sep 2026) of 20.5M outstanding (6 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

15%

3.0M shares sold short (30 Oct 2026) of 20.5M outstanding (6 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

17.0

3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.1%

2.9M shares sold short in the report before, 3.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

68%

68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

3

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-73%

$3.0M vs $10.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

5

5 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.0×

5 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 2.9M, 1.9× a year earlier

Price $22.19 on 20 Nov 2026, -40% over 12 months (12-month range $19.51 to $38.50)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $252K in the last 12 months (the 12 months before: $20.1M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $3.0M in the latest quarter, -73% on a year earlier.
Capital spending per quarter. Capital spending $121K in the latest quarter, +188% on a year earlier.
Institutional holders (13F filers). 102 13F filers reported holding it in the latest 13F quarter, +79% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.6M (2026-10-30); 2.4x the same period a year earlier
27 Oct 2026Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.5M (2026-10-15); 1.9x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 2.8M vs usual 1.5M (2026-09-30); 2.1x the same period a year earlier
13 Aug 20268-K and other filingsCompleted an acquisition or asset sale
5 Jun 20268-K and other filingsDirector or officer change
30 Mar 20268-K and other filingsDirector or officer change
30 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Mar 2026Sharp changeQuarterly revenue change: quarterly revenue change, 42.5M vs usual 7.9M (2025-12-31); 5.8x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 1.5M vs usual 31K (2026-01-30); 112.1x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 1.6M vs usual 30K (2026-01-15); 108.5x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 1.5M vs usual 28K (2025-12-31); 117.2x the same period a year earlier
30 Dec 2025Sharp changeShort interest spike: short interest spike, 1.4M vs usual 24K (2025-12-15); 102.6x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 1.3M vs usual 21K (2025-11-28); 81.2x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 1.3M vs usual 19K (2025-11-14); 113.2x the same period a year earlier
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 4.50 (2025-09-30); 10.0x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 1.3M vs usual 18K (2025-10-31); 162.2x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 1.5M vs usual 17K (2025-10-15); 93.4x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 1.4M vs usual 17K (2025-09-30); 76.0x the same period a year earlier
30 Sep 2025Sharp changeShort interest spike: short interest spike, 1.1M vs usual 17K (2025-09-15); 46.2x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 911K vs usual 17K (2025-08-29); 56.4x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 531K vs usual 17K (2025-08-15); 51.6x the same period a year earlier
9 Jun 20258-K and other filingsDirector or officer change
9 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jun 20248-K and other filingsDirector or officer change
15 Mar 20248-K and other filingsDirector or officer change
15 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jan 20248-K and other filingsA major agreement ended
12 Dec 2023Sharp changeShort interest spike: short interest spike, 528K vs usual 164K (2023-11-30); 0.5x the same period a year earlier
7 Dec 20238-K and other filingsDirector or officer change
7 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Nov 2023Sharp changeShort interest spike: short interest spike, 650K vs usual 164K (2023-11-15); 0.5x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 785K vs usual 164K (2023-10-31); 0.6x the same period a year earlier
29 Sep 20238-K and other filingsDelisting notice or listing transfer
30 May 20238-K and other filingsDirector or officer change
30 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Dec 20228-K and other filingsDirector or officer change
5 Oct 20228-K and other filingsDirector or officer change
20 Jul 20228-K and other filingsDirector or officer change
20 Jul 20228-K and other filingsRestructuring costs announced
27 May 20228-K and other filingsDirector or officer change
27 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Feb 20228-K and other filingsDirector or officer change
4 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: -$10K published
Month from 1 Apr 2022: -$22K published
Month from 1 Jun 2022: -$8K published
Month from 1 Jul 2022: -$4K published
Month from 1 Aug 2022: -$26K published
Month from 1 Mar 2023: -$5K published
Month from 1 Apr 2023: -$19K published
Month from 1 May 2023: -$41K published
Month from 1 Jun 2023: -$4K published
Month from 1 Jul 2023: -$903 published
Month from 1 Aug 2023: -$23K published
Month from 1 Oct 2023: -$5K published
Month from 1 Nov 2023: $283K published
Month from 1 Jan 2024: $510K published
Month from 1 Mar 2024: -$5K published
Month from 1 Apr 2024: -$24K published
Month from 1 May 2024: -$79K published
Month from 1 Jun 2024: $0 published
Month from 1 Jul 2024: $112K published
Month from 1 Aug 2024: -$25K published
Month from 1 Oct 2024: $141K published
Month from 1 Nov 2024: $371K published
Month from 1 Dec 2024: $20.1M published
Month from 1 Jan 2025: $50K published
Month from 1 Apr 2025: -$15K published
Month from 1 Oct 2025: $0 published
Month from 1 Apr 2026: -$14K published
Month from 1 Jun 2026: -$674 published
Month from 1 Nov 2026: -$238K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2025: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $0, -100% on a year earlier; public on 12 Mar 2022
Quarter ended 31 Mar 2023: $0; public on 9 May 2024
Quarter ended 30 Jun 2023: $0; public on 9 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 8 Nov 2024
Quarter ended 31 Dec 2023: $7.2M; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $5.8M; public on 9 May 2024
Quarter ended 30 Jun 2024: $8.5M; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $6.8M; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $7.4M, +2.7% on a year earlier; public on 21 Mar 2025
Quarter ended 31 Mar 2025: $9.4M, +63% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $9.6M, +13% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $10.8M, +58% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Mar 2026: $8.2M, -13% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $13.4M, +39% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $3.0M, -73% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $18K; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $0, -100% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $0; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $102K; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $0, -100% on a year earlier; public on 23 Mar 2023
Quarter ended 31 Mar 2023: $0; public on 9 May 2024
Quarter ended 30 Jun 2023: $48K; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $136K, +33% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $71K; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $14K; public on 9 May 2024
Quarter ended 30 Jun 2024: $14K, -71% on a year earlier; public on 9 Aug 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 9 May 2025
Quarter ended 30 Sep 2025: $42K; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $24K; public on 20 Mar 2026
Quarter ended 31 Mar 2026: $19K; public on 8 May 2026
Quarter ended 30 Sep 2026: $121K, +188% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 60; public on 14 Feb 2022
31 Mar 2022 report: 51; public on 16 May 2022
30 Jun 2022 report: 52; public on 15 Aug 2022
30 Sep 2022 report: 46; public on 14 Nov 2022
31 Dec 2022 report: 38; public on 14 Feb 2023
31 Mar 2023 report: 33; public on 15 May 2023
30 Jun 2023 report: 31; public on 14 Aug 2023
30 Sep 2023 report: 30; public on 14 Nov 2023
31 Dec 2023 report: 43; public on 14 Feb 2024
31 Mar 2024 report: 24; public on 15 May 2024
30 Jun 2024 report: 26; public on 14 Aug 2024
30 Sep 2024 report: 29; public on 14 Nov 2024
31 Dec 2024 report: 35; public on 14 Feb 2025
31 Mar 2025 report: 36; public on 15 May 2025
30 Jun 2025 report: 31; public on 14 Aug 2025
30 Sep 2025 report: 57; public on 14 Nov 2025
31 Dec 2025 report: 67; public on 17 Feb 2026
31 Mar 2026 report: 73; public on 15 May 2026
30 Jun 2026 report: 91; public on 14 Aug 2026
30 Sep 2026 report: 102; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 2.9M shares sold short in the 15 Oct 2026 report, 1.9× the same report last year; it also had 2.8M shares sold short in the 30 Sep 2026 report, 2.1× the same report last year. 3 sharp changes in all.
  • Short interest spike: had 2.9M shares sold short in the 15 Oct 2026 report, 1.9× the same report last year Public on 27 Oct 2026.
  • Insider net buying (open market): Insiders sold a net $252K in the last 12 months (the 12 months before: $20.1M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 85 insider trades

Last 90 days: 4 sales, $238K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
3 Nov 2026Jeanette M BjorkquistPFO and PAOSell727$19.62$14KForm 4
3 Nov 2026Nicole S WhiteChief Manufacturing OfficerSell2,593$19.62$51KForm 4
3 Nov 2026Anuj GaggarChief Medical OfficerSell2,593$19.62$51KForm 4
3 Nov 2026Jason A OkazakiCEO and PresidentSell6,202$19.62$122KForm 4
18 Jun 2026Jeanette M BjorkquistPFO and PAOSell29$23.25$674Form 4
31 Mar 2026Jeanette M BjorkquistPFO and PAOSell328$26.69$9KForm 4
31 Mar 2026Nicole S WhiteChief Manufacturing OfficerSell197$26.69$5KForm 4
3 Oct 2025Gilead Sciences, Inc.10% ownerBuy2,295,920Not filedNot filedForm 4

102 institutions reported shares at the end of Q3 2026, 94% of the shares outstanding; 21 opened a position, 12 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Gilead Sciences, Inc.5.0M24.3%$116.9MNo change
Farallon Capital Management, L.L.C.1.6M7.84%$37.7MNo change
Paradigm Biocapital Advisors LP1.6M7.59%$36.5MNo change
BlackRock, Inc.1.5M7.27%$35.0M+721K+94%
Ra Capital Management, L.P.1.0M4.98%$24.0MNo change
Parkman Healthcare Partners LLC796K3.89%$18.7M+75K+10%
Vanguard Capital Management LLC603K2.94%$14.2M+44K+7.9%
State Street Corp560K2.73%$13.1M+388K+225%
Millennium Management LLC490K2.39%$11.5M+191K+64%
Commodore Capital LP462K2.26%$10.9M-953K-67%

Company events

All 56 company events

In 12 months: 2 director or officer changes, 1 major agreement, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
13 Aug 2026Completed an acquisition or asset sale8-K
5 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
26 May 2026Signed a major agreement8-K
30 Mar 2026Director or officer change8-K
11 Aug 2025Signed a major agreementSame filing: sold shares privately8-K
9 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
3 Jan 2025Signed a major agreementSame filing: took on new debt8-K
19 Dec 2024Signed a major agreementSame filing: sold shares privately8-K

The 5 newest of 96 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

18 Nov 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Assembly Biosciences (ASMB): saw 30 13F filers open a new position in the quarter ended 30 Sep 2025, 10× the same quarter last year, while it had 1.5M shares sold short in the 30 Jan 2026 report, 112× the same report last year. Two unrelated kinds of activity within 112 days.

  • Short interest and volume: Short interest spike, became public on 25 Oct 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2025
  • Short interest and volume: Short interest spike, became public on 13 Nov 2025
  • Short interest and volume: Short interest spike, became public on 26 Nov 2025
  • Short interest and volume: Short interest spike, became public on 10 Dec 2025
  • Short interest and volume: Short interest spike, became public on 25 Dec 2025
  • Short interest and volume: Short interest spike, became public on 13 Jan 2026
  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
2023-09-30: 22023-12-31: 162024-03-31: 02024-06-30: 42024-09-30: 32024-12-31: 52025-03-31: 52025-06-30: 62025-09-30: 30
The quarter ended 30 Sep 2025 against the 8 quarters before it. this quarterearliernormal: 4.5
See the evidence (9 changes)

Short interest and volume: Short interest spike became public on 25 Oct 2025

Assembly Biosciences had 1.5M shares sold short in the 15 Oct 2025 report, 93× the same report last year.

This period
1.5M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
17K
Typical spread (median absolute deviation)
3,919
How far from its usual level
+30.3
Same report last year
16K
History used
2,847 days
2024-10-15: 16K2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M
the 15 Oct 2025 report24 earlier reportsnormal: 17K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

Assembly Biosciences saw 30 13F filers open a new position in the quarter ended 30 Sep 2025, 10× the same quarter last year.

This period
30 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
4.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+8.5
Same quarter last year
3
History used
4,018 days
2023-09-30: 22023-12-31: 162024-03-31: 02024-06-30: 42024-09-30: 32024-12-31: 52025-03-31: 52025-06-30: 62025-09-30: 30
the quarter ended 30 Sep 20258 earlier quartersnormal: 4.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 13 Nov 2025

Assembly Biosciences had 1.3M shares sold short in the 31 Oct 2025 report, 162× the same report last year.

This period
1.3M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
18K
Typical spread (median absolute deviation)
4,736
How far from its usual level
+25.4
Same report last year
7,949
History used
2,863 days
2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M
the 31 Oct 2025 report24 earlier reportsnormal: 18K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Nov 2025

Assembly Biosciences had 1.3M shares sold short in the 14 Nov 2025 report, 113× the same report last year.

This period
1.3M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
19K
Typical spread (median absolute deviation)
6,279
How far from its usual level
+25.7
Same report last year
12K
History used
2,877 days
2024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M
the 14 Nov 2025 report24 earlier reportsnormal: 19K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2025

Assembly Biosciences had 1.3M shares sold short in the 28 Nov 2025 report, 81× the same report last year.

This period
1.3M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
21K
Typical spread (median absolute deviation)
7,246
How far from its usual level
+25.4
Same report last year
16K
History used
2,891 days
2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M
the 28 Nov 2025 report24 earlier reportsnormal: 21K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Dec 2025

Assembly Biosciences had 1.4M shares sold short in the 15 Dec 2025 report, 103× the same report last year.

This period
1.4M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
24K
Typical spread (median absolute deviation)
9,700
How far from its usual level
+26.8
Same report last year
13K
History used
2,908 days
2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M
the 15 Dec 2025 report24 earlier reportsnormal: 24K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jan 2026

Assembly Biosciences had 1.5M shares sold short in the 31 Dec 2025 report, 117× the same report last year.

This period
1.5M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
28K
Typical spread (median absolute deviation)
14K
How far from its usual level
+30.3
Same report last year
13K
History used
2,924 days
2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M
the 31 Dec 2025 report24 earlier reportsnormal: 28K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jan 2026

Assembly Biosciences had 1.6M shares sold short in the 15 Jan 2026 report, 109× the same report last year.

This period
1.6M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
30K
Typical spread (median absolute deviation)
16K
How far from its usual level
+30.7
Same report last year
14K
History used
2,939 days
2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M
the 15 Jan 2026 report24 earlier reportsnormal: 30K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Feb 2026

Assembly Biosciences had 1.5M shares sold short in the 30 Jan 2026 report, 112× the same report last year.

This period
1.5M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
31K
Typical spread (median absolute deviation)
17K
How far from its usual level
+30.1
Same report last year
14K
History used
2,954 days
2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M2026-01-30: 1.5M
the 30 Jan 2026 report24 earlier reportsnormal: 31K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 11 Nov 2026Short interest and volume change

    had 3.0M shares sold short in the 30 Oct 2026 report, 2.4× the same report last year.

    Same report last year: 1.3M; its normal report is 1.6M.

    See the evidence
    This period
    3.0M (the 30 Oct 2026 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    214K
    How far from its usual level
    +4.7
    Same report last year
    1.3M
    History used
    3,227 days
    2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M2026-01-30: 1.5M2026-02-13: 1.5M2026-02-27: 1.5M2026-03-13: 1.5M2026-03-31: 1.5M2026-04-15: 1.5M2026-04-30: 1.6M2026-05-15: 1.5M2026-05-29: 1.7M2026-06-15: 1.9M2026-06-30: 2.4M2026-07-15: 2.3M2026-07-31: 2.3M2026-08-14: 2.3M2026-08-31: 2.1M2026-09-15: 2.1M2026-09-30: 2.8M2026-10-15: 2.9M2026-10-30: 3.0M
    the 30 Oct 2026 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 27 Oct 2026Short interest and volume change

    had 2.9M shares sold short in the 15 Oct 2026 report, 1.9× the same report last year.

    Same report last year: 1.5M; its normal report is 1.5M.

    See the evidence
    This period
    2.9M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    159K
    How far from its usual level
    +5.8
    Same report last year
    1.5M
    History used
    3,212 days
    2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M2026-01-30: 1.5M2026-02-13: 1.5M2026-02-27: 1.5M2026-03-13: 1.5M2026-03-31: 1.5M2026-04-15: 1.5M2026-04-30: 1.6M2026-05-15: 1.5M2026-05-29: 1.7M2026-06-15: 1.9M2026-06-30: 2.4M2026-07-15: 2.3M2026-07-31: 2.3M2026-08-14: 2.3M2026-08-31: 2.1M2026-09-15: 2.1M2026-09-30: 2.8M2026-10-15: 2.9M
    the 15 Oct 2026 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 10 Oct 2026Short interest and volume change

    had 2.8M shares sold short in the 30 Sep 2026 report, 2.1× the same report last year.

    Same report last year: 1.4M; its normal report is 1.5M.

    See the evidence
    This period
    2.8M (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    159K
    How far from its usual level
    +5.4
    Same report last year
    1.4M
    History used
    3,197 days
    2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M2026-01-30: 1.5M2026-02-13: 1.5M2026-02-27: 1.5M2026-03-13: 1.5M2026-03-31: 1.5M2026-04-15: 1.5M2026-04-30: 1.6M2026-05-15: 1.5M2026-05-29: 1.7M2026-06-15: 1.9M2026-06-30: 2.4M2026-07-15: 2.3M2026-07-31: 2.3M2026-08-14: 2.3M2026-08-31: 2.1M2026-09-15: 2.1M2026-09-30: 2.8M
    the 30 Sep 2026 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 13 Aug 2026Filings record

    Completed an acquisition or asset sale

  5. 5 Jun 2026Filings record

    Director or officer change

  6. 30 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 30 Mar 2026Filings record

    Director or officer change

  8. 26 Mar 2026Financials change

    reported revenue of $42.5M for the quarter ended 31 Dec 2025, 5.8× the same quarter last year.

    Same quarter last year: $7.4M; its normal quarter is $7.9M.

    See the evidence
    This period
    $42.5M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $7.9M
    Typical spread (median absolute deviation)
    $1.3M
    How far from its usual level
    +18.1
    Same quarter last year
    $7.4M
    History used
    3,197 days
    2023-12-31: $7.2M2024-03-31: $5.8M2024-06-30: $8.5M2024-09-30: $6.8M2024-12-31: $7.4M2025-03-31: $9.4M2025-06-30: $9.6M2025-09-30: $10.8M2025-12-31: $42.5M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $7.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  9. 11 Feb 2026Short interest and volume change

    had 1.5M shares sold short in the 30 Jan 2026 report, 112× the same report last year.

    Same report last year: 14K; its normal report is 31K.

    See the evidence
    This period
    1.5M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    31K
    Typical spread (median absolute deviation)
    17K
    How far from its usual level
    +30.1
    Same report last year
    14K
    History used
    2,954 days
    2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M2026-01-30: 1.5M
    the 30 Jan 2026 report24 earlier reportsnormal: 31K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 28 Jan 2026Short interest and volume change

    had 1.6M shares sold short in the 15 Jan 2026 report, 109× the same report last year.

    Same report last year: 14K; its normal report is 30K.

    See the evidence
    This period
    1.6M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    30K
    Typical spread (median absolute deviation)
    16K
    How far from its usual level
    +30.7
    Same report last year
    14K
    History used
    2,939 days
    2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M
    the 15 Jan 2026 report24 earlier reportsnormal: 30K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 13 Jan 2026Short interest and volume change

    had 1.5M shares sold short in the 31 Dec 2025 report, 117× the same report last year.

    Same report last year: 13K; its normal report is 28K.

    See the evidence
    This period
    1.5M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    28K
    Typical spread (median absolute deviation)
    14K
    How far from its usual level
    +30.3
    Same report last year
    13K
    History used
    2,924 days
    2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M
    the 31 Dec 2025 report24 earlier reportsnormal: 28K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 25 Dec 2025Short interest and volume change

    had 1.4M shares sold short in the 15 Dec 2025 report, 103× the same report last year.

    Same report last year: 13K; its normal report is 24K.

    See the evidence
    This period
    1.4M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    24K
    Typical spread (median absolute deviation)
    9,700
    How far from its usual level
    +26.8
    Same report last year
    13K
    History used
    2,908 days
    2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M
    the 15 Dec 2025 report24 earlier reportsnormal: 24K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 10 Dec 2025Short interest and volume change

    had 1.3M shares sold short in the 28 Nov 2025 report, 81× the same report last year.

    Same report last year: 16K; its normal report is 21K.

    See the evidence
    This period
    1.3M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    21K
    Typical spread (median absolute deviation)
    7,246
    How far from its usual level
    +25.4
    Same report last year
    16K
    History used
    2,891 days
    2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M
    the 28 Nov 2025 report24 earlier reportsnormal: 21K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 26 Nov 2025Short interest and volume change

    had 1.3M shares sold short in the 14 Nov 2025 report, 113× the same report last year.

    Same report last year: 12K; its normal report is 19K.

    See the evidence
    This period
    1.3M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    19K
    Typical spread (median absolute deviation)
    6,279
    How far from its usual level
    +25.7
    Same report last year
    12K
    History used
    2,877 days
    2024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M
    the 14 Nov 2025 report24 earlier reportsnormal: 19K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 18 Nov 2025several at once

    saw 30 13F filers open a new position in the quarter ended 30 Sep 2025, 10× the same quarter last year, while it had 1.5M shares sold short in the 30 Jan 2026 report, 112× the same report last year. Two unrelated kinds of activity within 112 days.

    See the evidence (9 changes)

    Short interest and volume: Short interest spike became public on 25 Oct 2025

    Assembly Biosciences had 1.5M shares sold short in the 15 Oct 2025 report, 93× the same report last year.

    This period
    1.5M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    17K
    Typical spread (median absolute deviation)
    3,919
    How far from its usual level
    +30.3
    Same report last year
    16K
    History used
    2,847 days
    2024-10-15: 16K2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M
    the 15 Oct 2025 report24 earlier reportsnormal: 17K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

    Assembly Biosciences saw 30 13F filers open a new position in the quarter ended 30 Sep 2025, 10× the same quarter last year.

    This period
    30 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    4.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +8.5
    Same quarter last year
    3
    History used
    4,018 days
    2023-09-30: 22023-12-31: 162024-03-31: 02024-06-30: 42024-09-30: 32024-12-31: 52025-03-31: 52025-06-30: 62025-09-30: 30
    the quarter ended 30 Sep 20258 earlier quartersnormal: 4.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 13 Nov 2025

    Assembly Biosciences had 1.3M shares sold short in the 31 Oct 2025 report, 162× the same report last year.

    This period
    1.3M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    18K
    Typical spread (median absolute deviation)
    4,736
    How far from its usual level
    +25.4
    Same report last year
    7,949
    History used
    2,863 days
    2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M
    the 31 Oct 2025 report24 earlier reportsnormal: 18K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Nov 2025

    Assembly Biosciences had 1.3M shares sold short in the 14 Nov 2025 report, 113× the same report last year.

    This period
    1.3M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    19K
    Typical spread (median absolute deviation)
    6,279
    How far from its usual level
    +25.7
    Same report last year
    12K
    History used
    2,877 days
    2024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M
    the 14 Nov 2025 report24 earlier reportsnormal: 19K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Dec 2025

    Assembly Biosciences had 1.3M shares sold short in the 28 Nov 2025 report, 81× the same report last year.

    This period
    1.3M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    21K
    Typical spread (median absolute deviation)
    7,246
    How far from its usual level
    +25.4
    Same report last year
    16K
    History used
    2,891 days
    2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M
    the 28 Nov 2025 report24 earlier reportsnormal: 21K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Dec 2025

    Assembly Biosciences had 1.4M shares sold short in the 15 Dec 2025 report, 103× the same report last year.

    This period
    1.4M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    24K
    Typical spread (median absolute deviation)
    9,700
    How far from its usual level
    +26.8
    Same report last year
    13K
    History used
    2,908 days
    2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M
    the 15 Dec 2025 report24 earlier reportsnormal: 24K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Jan 2026

    Assembly Biosciences had 1.5M shares sold short in the 31 Dec 2025 report, 117× the same report last year.

    This period
    1.5M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    28K
    Typical spread (median absolute deviation)
    14K
    How far from its usual level
    +30.3
    Same report last year
    13K
    History used
    2,924 days
    2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M
    the 31 Dec 2025 report24 earlier reportsnormal: 28K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    Assembly Biosciences had 1.6M shares sold short in the 15 Jan 2026 report, 109× the same report last year.

    This period
    1.6M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    30K
    Typical spread (median absolute deviation)
    16K
    How far from its usual level
    +30.7
    Same report last year
    14K
    History used
    2,939 days
    2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M
    the 15 Jan 2026 report24 earlier reportsnormal: 30K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    Assembly Biosciences had 1.5M shares sold short in the 30 Jan 2026 report, 112× the same report last year.

    This period
    1.5M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    31K
    Typical spread (median absolute deviation)
    17K
    How far from its usual level
    +30.1
    Same report last year
    14K
    History used
    2,954 days
    2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.4M2025-12-31: 1.5M2026-01-15: 1.6M2026-01-30: 1.5M
    the 30 Jan 2026 report24 earlier reportsnormal: 31K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  16. 14 Nov 2025Institutional holdings change

    saw 30 13F filers open a new position in the quarter ended 30 Sep 2025, 10× the same quarter last year.

    Same quarter last year: 3; its normal quarter is 4.5.

    See the evidence
    This period
    30 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    4.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +8.5
    Same quarter last year
    3
    History used
    4,018 days
    2023-09-30: 22023-12-31: 162024-03-31: 02024-06-30: 42024-09-30: 32024-12-31: 52025-03-31: 52025-06-30: 62025-09-30: 30
    the quarter ended 30 Sep 20258 earlier quartersnormal: 4.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  17. 13 Nov 2025Short interest and volume change

    had 1.3M shares sold short in the 31 Oct 2025 report, 162× the same report last year.

    Same report last year: 7,949; its normal report is 18K.

    See the evidence
    This period
    1.3M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    18K
    Typical spread (median absolute deviation)
    4,736
    How far from its usual level
    +25.4
    Same report last year
    7,949
    History used
    2,863 days
    2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M2025-10-31: 1.3M
    the 31 Oct 2025 report24 earlier reportsnormal: 18K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 25 Oct 2025Short interest and volume change

    had 1.5M shares sold short in the 15 Oct 2025 report, 93× the same report last year.

    Same report last year: 16K; its normal report is 17K.

    See the evidence
    This period
    1.5M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    17K
    Typical spread (median absolute deviation)
    3,919
    How far from its usual level
    +30.3
    Same report last year
    16K
    History used
    2,847 days
    2024-10-15: 16K2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M2025-10-15: 1.5M
    the 15 Oct 2025 report24 earlier reportsnormal: 17K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 10 Oct 2025Short interest and volume change

    had 1.4M shares sold short in the 30 Sep 2025 report, 76× the same report last year.

    Same report last year: 18K; its normal report is 17K.

    See the evidence
    This period
    1.4M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    17K
    Typical spread (median absolute deviation)
    3,694
    How far from its usual level
    +26.7
    Same report last year
    18K
    History used
    2,832 days
    2024-09-30: 18K2024-10-15: 16K2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M2025-09-30: 1.4M
    the 30 Sep 2025 report24 earlier reportsnormal: 17K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 4 Oct 2025Insiders record

    GILEAD SCIENCES, INC. (ten percent owner) bought 2,295,920 shares of ASMB (dated 3 Oct 2025)

  21. 25 Sep 2025Short interest and volume change

    had 1.1M shares sold short in the 15 Sep 2025 report, 46× the same report last year.

    Same report last year: 23K; its normal report is 17K.

    See the evidence
    This period
    1.1M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    17K
    Typical spread (median absolute deviation)
    3,694
    How far from its usual level
    +21.0
    Same report last year
    23K
    History used
    2,817 days
    2024-09-13: 23K2024-09-30: 18K2024-10-15: 16K2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K2025-09-15: 1.1M
    the 15 Sep 2025 report24 earlier reportsnormal: 17K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 11 Sep 2025Short interest and volume change

    had 911K shares sold short in the 29 Aug 2025 report, 56× the same report last year.

    Same report last year: 16K; its normal report is 17K.

    See the evidence
    This period
    911K (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    17K
    Typical spread (median absolute deviation)
    3,498
    How far from its usual level
    +17.9
    Same report last year
    16K
    History used
    2,800 days
    2024-08-30: 16K2024-09-13: 23K2024-09-30: 18K2024-10-15: 16K2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K2025-08-29: 911K
    the 29 Aug 2025 report24 earlier reportsnormal: 17K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 27 Aug 2025Short interest and volume change

    had 531K shares sold short in the 15 Aug 2025 report, 52× the same report last year.

    Same report last year: 10K; its normal report is 17K.

    See the evidence
    This period
    531K (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    17K
    Typical spread (median absolute deviation)
    3,237
    How far from its usual level
    +10.3
    Same report last year
    10K
    History used
    2,786 days
    2024-08-15: 10K2024-08-30: 16K2024-09-13: 23K2024-09-30: 18K2024-10-15: 16K2024-10-31: 7,9492024-11-15: 12K2024-11-29: 16K2024-12-13: 13K2024-12-31: 13K2025-01-15: 14K2025-01-31: 14K2025-02-14: 17K2025-02-28: 20K2025-03-14: 21K2025-03-31: 17K2025-04-15: 19K2025-04-30: 13K2025-05-15: 26K2025-05-30: 14K2025-06-13: 17K2025-06-30: 31K2025-07-15: 31K2025-07-31: 30K2025-08-15: 531K
    the 15 Aug 2025 report24 earlier reportsnormal: 17K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 9 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 9 Jun 2025Filings record

    Director or officer change

  26. 1 Jan 2025Insiders record

    Houghton Michael (director) bought 3,202 shares of ASMB ($49,983) (dated 31 Dec 2024)

  27. 24 Dec 2024Insiders record

    GILEAD SCIENCES, INC. (ten percent owner) bought 940,499 shares of ASMB ($20.1M) (dated 23 Dec 2024)

  28. 27 Nov 2024Insiders record

    Schornstein Alexander (ten percent owner) bought 25,000 shares of ASMB ($372,037) (dated 26 Nov 2024)

  29. 10 Oct 2024Insiders record

    Schornstein Alexander (ten percent owner) bought 10,000 shares of ASMB ($145,800) (dated 9 Oct 2024)

  30. 9 Jul 2024Insiders record

    Schornstein Alexander (ten percent owner) bought 9,000 shares of ASMB ($111,631) (dated 8 Jul 2024)

  31. 21 Jun 2024Insiders record

    GILEAD SCIENCES, INC. (ten percent owner) bought 179,500 shares of ASMB (dated 20 Jun 2024)

  32. 3 Jun 2024Filings record

    Director or officer change

  33. 15 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 15 Mar 2024Filings record

    Director or officer change

  35. 20 Jan 2024Insiders record

    Schornstein Alexander (ten percent owner) bought 645,080 shares of ASMB ($510,064) (dated 19 Jan 2024)

  36. 17 Jan 2024Filings record

    A major agreement ended

  37. 12 Dec 2023Short interest and volume change

    had 528K shares sold short in the 30 Nov 2023 report, 50% below the same report last year.

    Same report last year: 1.1M; its normal report is 164K.

    See the evidence
    This period
    528K (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    164K
    Typical spread (median absolute deviation)
    25K
    How far from its usual level
    +7.3
    Same report last year
    1.1M
    History used
    2,162 days
    2022-11-30: 1.1M2022-12-15: 188K2022-12-30: 218K2023-01-13: 325K2023-01-31: 153K2023-02-15: 151K2023-02-28: 151K2023-03-15: 129K2023-03-31: 164K2023-04-14: 303K2023-04-28: 171K2023-05-15: 161K2023-05-31: 288K2023-06-15: 296K2023-06-30: 163K2023-07-14: 165K2023-07-31: 186K2023-08-15: 158K2023-08-31: 126K2023-09-15: 144K2023-09-29: 134K2023-10-13: 138K2023-10-31: 785K2023-11-15: 650K2023-11-30: 528K
    the 30 Nov 2023 report24 earlier reportsnormal: 164K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 7 Dec 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 7 Dec 2023Filings record

    Director or officer change

  40. 28 Nov 2023Short interest and volume change

    had 650K shares sold short in the 15 Nov 2023 report, 49% below the same report last year.

    Same report last year: 1.3M; its normal report is 164K.

    See the evidence
    This period
    650K (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    164K
    Typical spread (median absolute deviation)
    25K
    How far from its usual level
    +9.7
    Same report last year
    1.3M
    History used
    2,147 days
    2022-11-15: 1.3M2022-11-30: 1.1M2022-12-15: 188K2022-12-30: 218K2023-01-13: 325K2023-01-31: 153K2023-02-15: 151K2023-02-28: 151K2023-03-15: 129K2023-03-31: 164K2023-04-14: 303K2023-04-28: 171K2023-05-15: 161K2023-05-31: 288K2023-06-15: 296K2023-06-30: 163K2023-07-14: 165K2023-07-31: 186K2023-08-15: 158K2023-08-31: 126K2023-09-15: 144K2023-09-29: 134K2023-10-13: 138K2023-10-31: 785K2023-11-15: 650K
    the 15 Nov 2023 report24 earlier reportsnormal: 164K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 93 entries; narrow the window or the kind of data to see older ones.

Not listed: 198 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001426800
Ticker
ASMB
Domain
assemblybio.com
Employer name
Assembly Biosciences, Inc. (1 unverified)
Hq location
CA|SOUTH SAN FRANCISCO|94080 (1 unverified)
Name
Assembly Biosciences, Inc, VENTRUS BIOSCIENCES INC
  • DOL H-1B labor condition applications and PERM certifications10 data points28 Jun 2021 to 5 May 2025
  • SEC Form 13F institutional holdings441 data points30 Sep 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)166 records11 Mar 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)975 data points6 Oct 2005 to 6 Nov 2026
  • SEC Form 4 insider transactions85 records, 220 data points12 Feb 2016 to 3 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026